Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- George E Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- George E Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Utah: - Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Sponsor: Massachusetts General Hospital
NCT ID: NCT06707493
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Ty…
Sponsor: Medical College of Wisconsin
NCT ID: NCT04838041
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Sponsor: CRISPR Therapeutics AG
NCT ID: NCT05643742
Sites in Utah: - University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. The investigators hypothesize that a go-slow gentle a…
Sponsor: University of Utah
NCT ID: NCT06517017
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05131022
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B ce…
Sponsor: Autolus Limited
NCT ID: NCT06173518
Sites in Utah: - Primary Children's Hospital — Salt Lake City, Utah
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Utah: - Massive Bio SYNERGY-AI site — Salt Lake City, Utah
Recruiting Industry
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qu…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06357754
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah